{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T09:40:17Z","timestamp":1738662017202,"version":"3.35.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.pharma.2024.09.010","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:21:37Z","timestamp":1727673697000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analyse de risques appliqu\u00e9e au suivi des concentrations des immunosuppresseurs chez les patients transplant\u00e9s pulmonaire"],"prefix":"10.1016","volume":"83","author":[{"given":"Agathe","family":"Landoas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romane","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Briault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierrick","family":"Bedouch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pharma.2024.09.010_bib0115","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.pharma.2024.09.010_bib0120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/phar.2716","article-title":"Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation","volume":"42","author":"Nelson","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.pharma.2024.09.010_bib0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1183\/09031936.03.00039203","article-title":"Immunosuppressive therapy after human lung transplantation","volume":"23","author":"Knoop","year":"2004","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.pharma.2024.09.010_bib0130","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/ajt.15251","article-title":"A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation","volume":"19","author":"Gottlieb","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.pharma.2024.09.010_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040622321993441","article-title":"Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes","volume":"12","author":"Patrucco","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"issue":"7","key":"10.1016\/j.pharma.2024.09.010_bib0140","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":"Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.pharma.2024.09.010_bib0145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.therap.2020.06.004","article-title":"Synth\u00e8se des recommandations de l\u2019International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) sur le suivi th\u00e9rapeutique pharmacologique du tacrolimus","volume":"75","author":"Lemaitre","year":"2020","journal-title":"Therapies"},{"issue":"1","key":"10.1016\/j.pharma.2024.09.010_bib0150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.trim.2014.05.002","article-title":"Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure\u2013response relationships, and clinical outcomes","volume":"31","author":"Shihab","year":"2014","journal-title":"Transpl Immunol"},{"issue":"6","key":"10.1016\/j.pharma.2024.09.010_bib0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","article-title":"Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range","volume":"73","author":"Kovarik","year":"2002","journal-title":"Transplantation"},{"issue":"Suppl. 14","key":"10.1016\/j.pharma.2024.09.010_bib0160","doi-asserted-by":"crossref","first-page":"S1732","DOI":"10.21037\/jtd.2019.03.83","article-title":"Detection, classification, and management of rejection after lung transplantation","volume":"11","author":"Parulekar","year":"2019","journal-title":"J Thorac Dis"},{"year":"2003","series-title":"Failure mode and effect analysis: FMEA from theory to execution","author":"Stamacis","key":"10.1016\/j.pharma.2024.09.010_bib0165"},{"issue":"2","key":"10.1016\/j.pharma.2024.09.010_bib0170","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.eswa.2012.08.010","article-title":"Risk evaluation approaches in failure mode and effects analysis: a literature review","volume":"40","author":"Liu","year":"2013","journal-title":"Expert Syst Appl"},{"issue":"4","key":"10.1016\/j.pharma.2024.09.010_bib0175","first-page":"315","article-title":"Approche comment\u00e9e par \u00e9tape pour r\u00e9aliser une AMDEC dans le cadre du circuit du m\u00e9dicament","volume":"53","author":"Boul\u00e9","year":"2018","journal-title":"Pharm Hosp Clin"},{"issue":"4","key":"10.1016\/j.pharma.2024.09.010_bib0180","first-page":"241","article-title":"L\u2019analyse des modes de d\u00e9faillance et de leurs effets\u00a0: une m\u00e9thode d\u2019analyse proactive des risques en \u00e9tablissement de sant\u00e9","volume":"41","author":"Poulin","year":"2008","journal-title":"Pharmactuel"},{"issue":"1\u20132","key":"10.1016\/j.pharma.2024.09.010_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19382014.2020.1856618","article-title":"Failure mode and effect analysis in human islet isolation: from the theoretical to the practical risk","volume":"13","author":"Perrier","year":"2021","journal-title":"Islets"},{"issue":"4","key":"10.1016\/j.pharma.2024.09.010_bib0190","article-title":"The use of failure mode effect and criticality analysis in a medication error subcommittee","volume":"29","author":"Williams","year":"1994","journal-title":"Hosp Pharm"},{"issue":"4","key":"10.1016\/j.pharma.2024.09.010_bib0195","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jep.13317","article-title":"Failure mode and effects analysis for proactive healthcare risk evaluation: a systematic literature review","volume":"26","author":"Liu","year":"2020","journal-title":"J Eval Clin Pract"},{"issue":"3","key":"10.1016\/j.pharma.2024.09.010_bib0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4212\/cjhp.3121","article-title":"Application of failure mode, effects, and criticality analysis to the medication-use process for temperature-sensitive drugs in a University Hospital","volume":"75","author":"Sakly","year":"2022","journal-title":"Can J Hosp Pharm"},{"issue":"1","key":"10.1016\/j.pharma.2024.09.010_bib0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharma.2019.06.006","article-title":"Analyse des risques a priori en unit\u00e9 de r\u00e9trocession hospitali\u00e8re\u00a0: focus sur le processus de dispensation","volume":"78","author":"Darcissac","year":"2020","journal-title":"Ann Pharm Fr"},{"issue":"5","key":"10.1016\/j.pharma.2024.09.010_bib0210","first-page":"406","article-title":"Perfusions continues et pompes intelligentes en n\u00e9onatologie\u00a0: une analyse \u00ab\u00a0pr\u00e9-post\u00a0\u00bb des modes de d\u00e9faillance, de leurs effets et de leur criticit\u00e9 (AMDEC)","volume":"68","author":"Delage","year":"2015","journal-title":"Can J Hosp Pharm"},{"issue":"6","key":"10.1016\/j.pharma.2024.09.010_bib0215","first-page":"376","article-title":"Analyse des modes de d\u00e9faillance, de leurs effets et de leur criticit\u00e9 dans le circuit du m\u00e9dicament\u00a0: revue de litt\u00e9rature","volume":"71","author":"Demers","year":"2018","journal-title":"Can J Hosp Pharm"},{"issue":"1145","key":"10.1016\/j.pharma.2024.09.010_bib0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/postgradmedj-2019-137484","article-title":"Application of Failure Mode and Effect Analysis (FMEA) to improve medication safety: a systematic review","volume":"97","author":"Anjalee","year":"2021","journal-title":"Postgrad Med J"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T09:06:19Z","timestamp":1738659979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0003450924001433"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.09.010","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyse de risques appliqu\u00e9e au suivi des concentrations des immunosuppresseurs chez les patients transplant\u00e9s pulmonaire","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}